AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (28.7 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Autonomous Microrobots for Spatiotemporally Active Therapeutic Delivery and Controlled Release

Shihao Zhong1,2,Anping Wu3,Shanming Bai1,2Henwei Huang4,5( )Toshio Fukuda6Huaping Wang1,2( )
Intelligent Robotics Institute, School of Mechatronical Engineering, Beijing Institute of Technology, Beijing 100081, China
Key Laboratory of Biomimetic Robots and Systems (Beijing Institute of Technology), Ministry of Education, Beijing 100081, China
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China
School of Electrical and Electronic Engineering, Nanyang Technological University, Singapore 639798, Singapore
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore
Department of Micronano Systems Engineering, Nagoya University, Nagoya 464-8603, Japan

†These authors contributed equally to this work.

Show Author Information

Abstract

The clinical efficacy of many conventional passive drug delivery systems is frequently constrained by their low targeting efficiency, important off-target toxicity, and inadequate capacity for traversing biological barriers. Autonomous microrobots, as miniature intelligent platforms capable of active navigation and on-demand responsiveness, offer an active delivery strategy for achieving spatiotemporally precise targeted therapy. This review aims to systematically consolidate and critique the theoretical foundations, key technologies, cutting-edge applications, and future challenges of this emergent interdisciplinary field. We first provide an in-depth analysis of the technological frameworks underpinning the 2 core functionalities: targeted delivery and on-demand release. This encompasses a diverse array of propulsion and navigation strategies—from chemical and physical fields to biohybrid systems—as well as programmed drug release mechanisms responsive to endogenous and exogenous stimuli. Building on this, we introduce a hierarchical paradigm organized by biological-barrier traversal capability to review the preclinical progress of microrobots, from localized delivery in accessible body cavities to deep-tissue and trans-barrier applications. This function-oriented framework more directly links microrobot design to the progressive physiological constraints encountered in vivo, thereby providing a more integrated and translationally relevant perspective on biomedical applications and clinical potential. Concurrently, this paper examines the bottlenecks impeding their clinical translation, including biosafety, systemic controllability, and regulatory science. Looking forward, the deep integration of microrobotics with smart materials, artificial intelligence, and theranostic systems is poised to cultivate a new generation of intelligent medical robots capable of personalized treatment via closed-loop manners.

References

【1】
【1】
 
 
Cyborg and Bionic Systems
Article number: 0617

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhong S, Wu A, Bai S, et al. Autonomous Microrobots for Spatiotemporally Active Therapeutic Delivery and Controlled Release. Cyborg and Bionic Systems, 2026, 7: 0617. https://doi.org/10.34133/cbsystems.0617

6

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

Received: 14 March 2026
Revised: 10 May 2026
Accepted: 14 May 2026
Published: 29 June 2026
© 2026 Shihao Zhong et al. Exclusive licensee Beijing Institute of Technology Press. No claim to original U.S. Government Works.